Pharmaceutical Executive-11-01-2004

Sometimes the loss of revenue from a branded drug can outweigh the royalty stream from an authorized generic.

If trial results never reach the public, researchers could waste time repeating lines of inquiry that have already proven unsuccessful.

Lifecycle management and line extensions helped the Percocet franchise generate steady annual growth, rising from $40 million in 1997 sales to $214 million in 2003, despite the fact that it had no patent protection.

We didn't think, even before Vioxx got pulled, that Arcoxia would ever get approved because we thought it had cardiovascular signals-and because of the debate over Vioxx for the last five years. Now, unequivocally, we don't believe it will be approved.

Finger pointing has begun in earnest, as Congress tries to decide who ignored what warning, who silenced what staff scientist, and who broke what law. But recent events also raise real long-term issues for industry.

The global pain market will reach nearly $29.8 billion in 2008, of which $21.8 billion will come from the United States.

Reeve had done something that many of us who communicate about health issues try in vain to accomplish.

Patient Centric

Junction 11 Advertising continued its winning streak with direct messages and haunting images that have become characteristic of the Risperdal campaign.